← Leaderboards
Judith Ann Aberg
University Of California San Francisco
$20,303,532
Attributed
$20,303,532
Total exposure
86
Grants
58
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.1M · FY2005–14$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$20,303,532 · 86
By mechanism
U01$12,522,944 · 2
M01$4,443,308 · 82
UM1$2,872,311 · 1
R21$464,969 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Silvija I Staprans$7,069,069
- Martin G Tauber$199,113
Others in their field
Top investigators on “Source”
- Richard A Gibbs · Baylor College Of Medicine$285,393,445
- David Heimbrook · Leidos Biomedical Research, Inc.$233,184,481
- Robert B Gagosian · Consortium For Ocean Leadership, Inc$232,495,072
- Jeffrey P Krischer · University Of South Florida$224,745,020
- Albert Lazzarini · California Institute Of Technology$202,317,285
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$155,571,437
Research focus
SourceAids Clinical Trial GroupResearch PersonnelFundingComputer Retrieval Of Information On Scientific Projects DatabaseGrantInstitutionResourcesUnited States National Institutes Of HealthWeekRandomizedClinical TrialsInfectionEnrollmentClinical ResearchProtocols, TreatmentPharmaceutical PreparationsSafetyAntiretroviral TherapyAnti-Retroviral AgentsUpper ArmHiv-1PersonsMonitor
Grant awards (100)
New York University HIV/AIDS Clinical Trial Unit$67,226
UM1 · FY2014 · AI · contact PI
New York University HIV/AIDS Clinical Trial Unit$1,344,582
UM1 · FY2013 · AI · contact PI
New York University HIV/AIDS Clinical Trial Unit$1,460,503
UM1 · FY2012 · AI · contact PI
New York University HIV/AIDS Clinical Trial Unit$1,514,874
U01 · FY2011 · AI · contact PI
New York University HIV/AIDS Clinical Trial Unit$1,625,568
U01 · FY2010 · AI · contact PI
Virologic and Serologic Outcomes of Persons with HIV and HBV co-infection on Mono$169,000
R21 · FY2010 · AI · contact PI
New York University HIV/AIDS Clinical Trial Unit$1,600,805
U01 · FY2009 · AI · contact PI
Virologic and Serologic Outcomes of Persons with HIV and HBV co-infection on Mono$295,969
R21 · FY2009 · AI · contact PI
New York University HIV/AIDS Clinical Trial Unit$1,488,404
U01 · FY2008 · AI · contact PI
CLINICAL TRIAL: ACTG A5202: EFAVIRENZ OR ATAZANAVIR WITH RITONAVIR IN ARV-NAIVE$557,330
M01 · FY2008 · RR · contact PI
ADULT AIDS CLINICAL TRIAL GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS PROTOCOL$398,098
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: ACTG A5212: PALIFERMIN FOR INADEQUATE CD4+ LYMPHOCYTE RECOVERY$334,400
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: ACTG A5229: URIDINE SUPPLEMENTATION IN HIV LIPOATROPHY$136,941
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: ACTG A5220: USING GM-CSF TO IMPROVE IMMUNE RESPONSE TO HEPATITIS$63,698
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: ACTG A5175: ONCE-DAILY ARV THERAPY FOR HIV-1 IN RESOURCE-LIMITED$57,326
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: ACTG A5164:IMMEDIATE VS DELAYED ART FOR HIV-INFECTED PATIENTS WI$22,290
M01 · FY2008 · RR · contact PI
ACTG A5206: IMPACT ON DYSLIPIDEMIA OF ADDING TENOFOVIR TO ARV THERAPY IN HIV$15,927
M01 · FY2008 · RR · contact PI
ACTG A5223: SEX DIFFERENCES IN LOPINAVIR/RITONAVIR PHARMACOKINETICS$15,927
M01 · FY2008 · RR · contact PI
ACTG A5244: EFFECT OF RALTEGRAVIR ON VIREMIA IN HIV SUBJECTS INFECTION ON ART$9,554
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: ACTG A5211: SCH 417690 IN HIV-INFECTED, TREATMENT-EXPERIENCED SU$9,554
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: ACTG A5197: ANTIRETROVIRAL EFFECT OF IMMUNIZATION WITH THE MRK A$9,554
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: ACTG A5241: OPTIMIZED TREATMENT THAT INCLUDES OR OMITS NRTIS (OP$3,182
M01 · FY2008 · RR · contact PI
ACTG A5221: IMMEDIATE VS DEFERRED ANTIRETROVIRAL THERAPY FOR HIV/TUBERCULOSIS$3,182
M01 · FY2008 · RR · contact PI
New York University HIV/AIDS Clinical Trial Unit$1,273,058
U01 · FY2007 · AI · contact PI
ACTG A5202: EFAVIRENZ OR ATAZANAVIR WITH RITONAVIR IN ARV-NAIVE SUBJECTS (AIDS)$338,020
M01 · FY2007 · RR · contact PI
ADULT AIDS CLINICAL TRIAL GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS PROTOCOL$263,394
M01 · FY2007 · RR · contact PI
ACTG A5197: ANTIRETROVIRAL EFFECT OF IMMUNIZATION WITH THE MRK AD5 HIV-1 GAG VA$79,018
M01 · FY2007 · RR · contact PI
ACTG A5175: ONCE-DAILY ARV THERAPY FOR HIV-1 IN RESOURCE-LIMITED SETTINGS$48,287
M01 · FY2007 · RR · contact PI
ACTG A5164:IMMEDIATE VS DELAYED ART FOR HIV-INFECTED PATIENTS WITH ACUTE OT$39,509
M01 · FY2007 · RR · contact PI
ACTG A5211: SCH 417690 IN HIV-INFECTED, TREATMENT-EXPERIENCED SUBJECTS$37,316
M01 · FY2007 · RR · contact PI
ACTG A5229: URIDINE SUPPLEMENTATION IN HIV LIPOATROPHY$35,117
M01 · FY2007 · RR · contact PI
ACTG A5209: EZETIMIBE PLUS STATINS TO LOWER CHOLESTEROL IN HIV-INFECTED SUBJECTS$28,532
M01 · FY2007 · RR · contact PI
ACTG A5220: USING GM-CSF TO IMPROVE IMMUNE RESPONSE TO HEPATITIS B VACCINE$24,147
M01 · FY2007 · RR · contact PI
ACTG A5223: SEX DIFFERENCES IN LOPINAVIR/RITONAVIR PHARMACOKINETICS$21,947
M01 · FY2007 · RR · contact PI
ACTG A5206: IMPACT ON DYSLIPIDEMIA OF ADDING TENOFOVIR TO ARV THERAPY IN HIV$19,755
M01 · FY2007 · RR · contact PI
ACTG 362: AZITHROMYCIN PROPHYLAXIS FOR PRIMARY PREVENTION OF MAC IN AIDS$17,562
M01 · FY2007 · RR · contact PI
ACTG A5068: WITHDRAWL OF ANTIRETROVIRALS + HIV VACCINE IN SUBJECTS W/ CD4>400$10,977
M01 · FY2007 · RR · contact PI
ACTG A5142: COMPARISON OF THREE ANTIVIRAL REGIMENS FOR INITIAL THERAPY OF HIV-1$4,392
M01 · FY2007 · RR · contact PI
AACTG A5216: CYCLOSPORINE A/TRIZIVIR/KALETRA VERSUS TRIZIVIR/KALETRA ALONE$4,392
M01 · FY2007 · RR · contact PI
ACTG A5178: LONG-TERM ANTIVIRAL MANAGEMENT OF HCV AND HIV-1 COINFECTED SUBJECTS$2,193
M01 · FY2007 · RR · contact PI
ADULT AIDS CLINICAL TRIALS UNIT$1,526,915
U01 · FY2006 · AI · contact PI
ADULT AIDS CLINICAL TRIAL GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS PROTOCOL$250,753
M01 · FY2006 · RR · contact PI
ACTG A5211: SCH 417690 IN HIV-INFECTED, TREATMENT-EXPERIENCED SUBJECTS$130,391
M01 · FY2006 · RR · contact PI
ACTG A5202: EFAVIRENZ OR ATAZANAVIR WITH RITONAVIR IN ARV-NAIVE SUBJECTS (AIDS)$78,571
M01 · FY2006 · RR · contact PI
ACTG A5178: LONG-TERM ANTIVIRAL MANAGEMENT OF HCV AND HIV-1 COINFECTED SUBJECTS$41,790
M01 · FY2006 · RR · contact PI
ACTG A5197: ANTIRETROVIRAL EFFECT OF IMMUNIZATION WITH THE MRK AD5 HIV-1 GAG VA$38,450
M01 · FY2006 · RR · contact PI
AACTG A5216: CYCLOSPORINE A/TRIZIVIR/KALETRA VERSUS TRIZIVIR/KALETRA ALONE$38,450
M01 · FY2006 · RR · contact PI
ACTG 371: 3TC/ZDV/ABC/APV IN ACUTE HIV INFECTION OR SEROCONVERSION$31,760
M01 · FY2006 · RR · contact PI
ACTG A5164:IMMEDIATE VS DELAYED ART FOR HIV-INFECTED PATIENTS WITH ACUTE OT$26,745
M01 · FY2006 · RR · contact PI
ACTG A5142: COMPARISON OF THREE ANTIVIRAL REGIMENS FOR INITIAL THERAPY OF HIV-1$26,745
M01 · FY2006 · RR · contact PI
ACTG A5223: SEX DIFFERENCES IN LOPINAVIR/RITONAVIR PHARMACOKINETICS$21,730
M01 · FY2006 · RR · contact PI
ACTG A5068: WITHDRAWL OF ANTIRETROVIRALS + HIV VACCINE IN SUBJECTS W/ CD4>400$16,715
M01 · FY2006 · RR · contact PI
ACTG A5206: IMPACT ON DYSLIPIDEMIA OF ADDING TENOFOVIR TO ARV THERAPY IN HIV$16,715
M01 · FY2006 · RR · contact PI
ACTG A5073:TWICE DAILY -V- ONCE DAILY HAARTAND SELF-ADMINISTERED VERSUS DOT$15,045
M01 · FY2006 · RR · contact PI
ACTG A5146: THERAPEUTIC DRUG MONITORING IN SUBJECTS WITH A LOW NIQ TO PIS (AIDS)$15,045
M01 · FY2006 · RR · contact PI
ACTG A5175: ONCE-DAILY ARV THERAPY FOR HIV-1 IN RESOURCE-LIMITED SETTINGS$13,375
M01 · FY2006 · RR · contact PI
ACTG A5173:CLEARANCE OF HIV-1 IN CD4+ CELLS OF SUBJECTS ON T-20 PLUS ORAL AR$11,700
M01 · FY2006 · RR · contact PI
ACTG A5209: EZETIMIBE PLUS STATINS TO LOWER CHOLESTEROL IN HIV-INFECTED SUBJECTS$10,030
M01 · FY2006 · RR · contact PI
ACTG A5095: 3 PROTEASE INHIBITOR-SPARING REGIMENS FOR INITIAL TREATMENT OF HIV$10,030
M01 · FY2006 · RR · contact PI
ACTG A5170: PREDICTORS OF DISEASE PROGRESSION IN SUBJECTS WHO DISCONTINUE ART$6,685
M01 · FY2006 · RR · contact PI
ACTG 362: AZITHROMYCIN PROPHYLAXIS FOR PRIMARY PREVENTION OF MAC IN AIDS$5,015
M01 · FY2006 · RR · contact PI
ACTG A5030: VALGANCICLOVIR FOR PRE-EMPTIVE THERAPY FOR CYTOMEGALOVIRUS (AIDS)$3,345
M01 · FY2006 · RR · contact PI
ACTG A5163: ALENDRONATE IN HIV SUBJECTS WITH DECREASED BONE MINERAL DENSITY$3,345
M01 · FY2006 · RR · contact PI
ACTG A5029: HUMAN PAPILLOMA VIRUS IN ANTIRETROVIRAL NAIVE HIV+ WOMEN ON HAART$3,104
M01 · FY2006 · RR · contact PI
EFFECT OF THYMIDINE ANALOGUE CHANGE TO NUCLEOSIDE-SPARING REGIMEN ON FAT WASTING$1,670
M01 · FY2006 · RR · contact PI
ADULT AIDS CLINICAL TRIALS UNIT$1,724,582
U01 · FY2005 · AI
ACTG 371: 3TC/ZDV/ABC/APV IN ACUTE HIV INFECTION OR SEROCONVERSION$190,715
M01 · FY2005 · RR
ADULT AIDS CLINICAL TRIAL GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS PROTOCOL$171,386
M01 · FY2005 · RR
ACTG A5073:TWICE DAILY -V- ONCE DAILY HAARTAND SELF-ADMINISTERED VERSUS DOT$130,152
M01 · FY2005 · RR
ACTG A5095: 3 PROTEASE INHIBITOR-SPARING REGIMENS FOR INITIAL TREATMENT OF HIV$130,152
M01 · FY2005 · RR
ACTG A5164:IMMEDIATE VS DELAYED ART FOR HIV-INFECTED PATIENTS WITH ACUTE OT$100,513
M01 · FY2005 · RR
ACTG A5068: WITHDRAWL OF ANTIRETROVIRALS + HIV VACCINE IN SUBJECTS W/ CD4>400$72,164
M01 · FY2005 · RR
ACTG A5142: COMPARISON OF THREE ANTIVIRAL REGIMENS FOR INITIAL THERAPY OF HIV-1$47,678
M01 · FY2005 · RR
ACTG A5170: PREDICTORS OF DISEASE PROGRESSION IN SUBJECTS WHO DISCONTINUE ART$36,080
M01 · FY2005 · RR
ACTG A5186: EFFECT OF FISH OIL AND FENOFIBRATE ON TRIGLYCERIDE LEVELS$15,463
M01 · FY2005 · RR
EFFECT OF THYMIDINE ANALOGUE CHANGE TO NUCLEOSIDE-SPARING REGIMEN ON FAT WASTING$15,463
M01 · FY2005 · RR
ACTG A5173:CLEARANCE OF HIV-1 IN CD4+ CELLS OF SUBJECTS ON T-20 PLUS ORAL AR$14,176
M01 · FY2005 · RR
ACTG A5211: SCH 417690 IN HIV-INFECTED, TREATMENT-EXPERIENCED SUBJECTS$12,885
M01 · FY2005 · RR
ACTG A5163: ALENDRONATE IN HIV SUBJECTS WITH DECREASED BONE MINERAL DENSIT$11,598
M01 · FY2005 · RR
ACTG A5146: THERAPEUTIC DRUG MONITORING IN SUBJECTS WITH A LOW NIQ TO PIS$10,310
M01 · FY2005 · RR
ACTG 362: AZITHROMYCIN PROPHYLAXIS FOR PRIMARY PREVENTION OF MAC IN AIDS$10,310
M01 · FY2005 · RR
ACTG A5178: LONG-TERM ANTIVIRAL MANAGEMENT OF HCV AND HIV-1 COINFECTED SUBJECTS$9,019
M01 · FY2005 · RR
ACTG A5029: HUMAN PAPILLOMA VIRUS IN ANTIRETROVIRAL NAIVE HIV+ WOMEN ON HAART$5,153
M01 · FY2005 · RR
AACTG A5216: CYCLOSPORINE A/TRIZIVIR/KALETRA VERSUS TRIZIVIR/KALETRA ALONE$5,153
M01 · FY2005 · RR
ACTG A5030: VALGANCICLOVIR FOR PRE-EMPTIVE THERAPY FOR CYTOMEGALOVIRUS$3,866
M01 · FY2005 · RR
ACTG A5092S: PHARMACOKINETIC EFFECTS OF RBV ON ZDV OR D4T TRIPHOSPHATE FORMATION$2,579
M01 · FY2005 · RR
ACTG A5197: ANTIRETROVIRAL EFFECT OF IMMUNIZATION WITH THE MRK AD5 HIV-1 GAG VA$2,579
M01 · FY2005 · RR
ACTG A5128: OBTAINING INFORMED CONSENT TO USE STORED HUMAN BIOLOGICAL MATERIALS$1,287
M01 · FY2005 · RR
PREDICTIVE VALUE OF PK-ADJUSTED PHENOTYPIC SUSCEPTIBILITY ON ANTIRETROVIRAL RESP$1,287
M01 · FY2005 · RR
ADULT AIDS CLINICAL TRIALS UNIT$1,768,738
U01 · FY2004 · AI
KINETIC INTERACTION OF APV, EFV, &A SECOND PI$6,656
M01 · FY2004 · RR
EVALUATION OF POTENTIAL PHARMACOKINETIC INTERACTIONS BETWEEN PIS &CCBS$6,656
M01 · FY2004 · RR
A STUDY TO EVALUATE THE EFFECTS OF HYDROCHLOROTHIAZIDE, LISINOPRIL, AND AMOLDOPI$739
M01 · FY2004 · RR
DISCONTINUATION ANTIFUNGAL FOR CRYPTOCOCCAL MENINGITIS$0
M01 · FY2002 · RR
DISCONTINUATION ANTIFUNGAL FOR CRYPTOCOCCAL MENINGITIS$0
M01 · FY2002 · RR
DISCONTINUATION ANTIFUNGAL FOR CRYPTOCOCCAL MENINGITIS$0
M01 · FY2001 · RR
SAFETY, PKS, &ANTIFUNGAL EFFECTS OF BMS 207147 IN HIV+ PATIENTS$564
M01 · FY2000 · RR
DISCONTINUATION ANTIFUNGAL FOR CRYPTOCOCCAL MENINGITIS$0
M01 · FY2000 · RR
DISCONTINUATION ANTIFUNGAL FOR CRYPTOCOCCAL MENINGITIS$0
M01 · FY2000 · RR
DISCONTINUATION ANTIFUNGAL FOR CRYPTOCOCCAL MENINGITIS$0
M01 · FY2000 · RR